However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

A 13-week extension of the previous phase 1/2 trial is also ongoing ... that is Metsera’s answer to the sector’s search for a ...

a statistic which holds for both daily orals as well as weekly injectables. GLP-1 drugs have already improved the health of ...

fully-biased injectable GLP-1 RA underway Metsera recently reported significant and durable weight loss from the Phase 1/2 trial of MET-097i, a novel, fully-biased, potential once-monthly injectable ...

"Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601, ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

The drug semaglutide, commonly known by the brand names Ozempic or Wegovy, was originally developed to help people with type 2 diabetes manage their ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

Ahead of World Diabetes Day, Doctors Without Borders/Médecins Sans Frontières (MSF) called for all insulin manufacturers to provide injection pen devices at $1 per pen ... Novo Nordisk's BLA filing ...

And once again thank you for participating on the Altimmune ... Let me recap the plan designed of the four trials that we ...